Failure Rate of Anti-Tumor Necrosis Factor α Biologics in Very Early Onset Inflammatory Bowel Disease

Inflamm Bowel Dis. 2024 Mar 1;30(3):510-512. doi: 10.1093/ibd/izad313.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biological Products* / adverse effects
  • Crohn Disease*
  • Humans
  • Necrosis
  • Tumor Necrosis Factor-alpha

Substances

  • Biological Products
  • Tumor Necrosis Factor-alpha

Grants and funding